Liveome, a subsidiary of Medytox specializing in new drug development, said it registered a patent in China for its microbial gene therapy development platform and LIV001, an inflammatory bowel disease (IBD) treatment.

Following patents in Korea and Japan, this latest registration secures Liveome's intellectual property rights across significant Asian markets.

Given the rising prevalence of IBD in North America, Europe, and now Asia, securing a patent in China further solidifies Liveome's strategic positioning for global commercialization.

The company continues to pursue international patents for its platform technology and treatments. Last year, Liveome obtained similar patents in both the U.S. and Australia.

Liveome is utilizing its proprietary eLBP platform to design and produce next-generation microbial gene therapies through targeted gene editing.

LIV001, a microbial gene therapy developed using this platform, introduces a peptide VIP gene with immunomodulatory properties into microorganisms to treat IBD.

Following the successful completion of a phase I clinical trial in Australia, Liveome is now preparing for a multinational trial to evaluate the drug's efficacy further.

Meanwhile, Liveome's CTO Kim Yeung-hyen is set to unveil further details of the company's development journey at the Bio Korea 2024 microbiome session on Friday.